AnswersPublished16 sources
FDA Approves Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer: Complete Guide to the June 2026 Decision
On June 24, 2026, the FDA approved Trodelvy for two first line indications in metastatic triple negative breast cancer (mTNBC): as monotherapy for patients not eligible for PD 1/PD L1 inhibitors (based on ASCENT 03, 3... The European Commission approved Trodelvy as first line monotherapy the day before, on June 23,...
Published byEdited with DeepSeek-V4-FlashImages generated with GPT Image 1.5
Research answer
Key takeaways
- On June 24, 2026, the FDA approved Trodelvy for two first line indications in metastatic triple negative breast cancer (mTNBC): as monotherapy for patients not eligible for PD 1/PD L1 inhibitors (based on ASCENT 03, 3...
- The European Commission approved Trodelvy as first line monotherapy the day before, on June 23, 2026, making it the first ADC and the first new treatment option in 20 years for certain first line mTNBC patients in Eur...
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: Search & fact-check with cited sources for What are the key details of the FDA's approval of Gilead Sciences' Trodelvy (sacituzumab goviteca. Article summary: On **June 24, 2026**, the FDA approved Trodelvy (sacituzumab govitecan-hziy) for two first-line indications in metastatic triple-negative breast cancer (mTNBC), supported by the Phase 3 ASCENT-03 and ASCENT-04 trials [4]. Topic tags: general, government, academic, general web. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts w
On June 24, 2026, the FDA approved Trodelvy (sacituzumab govitecan-hziy) for two first-line indications in metastatic triple-negative breast cancer (mTNBC) . The decision expands Trodelvy from a third-line-plus therapy to a front-line backbone for all patients regardless of PD-L1 status, supported by the Phase 3 ASCENT-03 and ASCENT-04 trials . The very next day, the European Commission approved Trodelvy as a first-line monotherapy in Europe . Here is what clinicians, patients, and researchers need to know about this landmark regulatory decision.
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "FDA Approves Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer: Complete Guide to the June 2026 Decision"?
On June 24, 2026, the FDA approved Trodelvy for two first line indications in metastatic triple negative breast cancer (mTNBC): as monotherapy for patients not eligible for PD 1/PD L1 inhibitors (based on ASCENT 03, 3...
What are the key points to validate first?
On June 24, 2026, the FDA approved Trodelvy for two first line indications in metastatic triple negative breast cancer (mTNBC): as monotherapy for patients not eligible for PD 1/PD L1 inhibitors (based on ASCENT 03, 3... The European Commission approved Trodelvy as first line monotherapy the day before, on June 23, 2026, making it the first ADC and the first new treatment option in 20 years for certain first line mTNBC patients in Eur...